Blood Brain Barrier Market Assessment 2024-2035, Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions [Yahoo!...
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering. The Blood Brain Barrier Market is valued at USD 36 million in 2024 growing at a CAGR of 49% during the forecast period 2024-2035. The focus of blood-brain barrier drugs and technologies is to address the challenges posed by the selective nature of the blood-brain barrier, enabling therapeutic agents to reach the brain directly. Recent years have seen increased research and investment to understand and overcome these challenges, driven by rising incidences of neurological diseases like Alzheimer's and Parkinson's. This trend is expected to drive demand for therapies that bypass the blood-brain barrier, fostering innovation and expanding the market in this area. Innovations include drug delivery systems, nanoparticles, and medical devices aimed at enhancing treatment efficac
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics Inc. (NASDAQ: DNLI) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $31.00 price target on the stock.MarketBeat
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp AlfaGlobeNewswire
- Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™ [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™GlobeNewswire
DNLI
Earnings
- 11/6/24 - Miss
DNLI
Sec Filings
- 2/13/25 - Form SCHEDULE
- 2/12/25 - Form SCHEDULE
- 1/13/25 - Form 8-K
- DNLI's page on the SEC website